Nutriband (US:NTRB) Globenewswire·2025-10-27 11:00Core Points - Nutriband Inc. has announced the return of founder Gareth Sheridan as CEO, effective immediately, after Serguei Melnik temporarily took over the role from August 10 to October 27, 2025 [1] - The company is focused on advancing its lead product, AVERSA Fentanyl, towards a target NDA filing in 2026 [1] Group 1: Product Overview - AVERSA Fentanyl is positioned to be the world's first abuse-deterrent opioid patch, aimed at preventing abuse and reducing accidental exposure risks associated with transdermal fentanyl patches [2] - The product has the potential to achieve peak annual sales in the US ranging from $80 million to $200 million, with plans to expand into major global medical markets [2] Group 2: Technology and Intellectual Property - The AVERSA abuse-deterrent technology is protected by a comprehensive international intellectual property portfolio, with patents issued in 46 countries, including the US, Europe, Japan, and China [3] - This technology incorporates aversive agents into transdermal patches to mitigate the risks of abuse, misuse, and accidental exposure while ensuring accessibility for patients in need [3][4] Group 3: Company Background - Nutriband Inc. specializes in developing a range of transdermal pharmaceutical products, with AVERSA Fentanyl being the lead product under development [4] - The AVERSA technology can be integrated into any transdermal patch to enhance safety and prevent misuse of drugs with abuse potential [4]